Establishment of basal cell carcinoma animal model in Chinese tree shrew (*Tupaia belangeri chinensis*)

Li-Ping Jiang¹,²,#, Qiu-Shuo Shen¹,²,#, Cui-Ping Yang¹,²,* , Yong-Bin Chen¹,²*

¹ Key Laboratory of Animal Models and Human Disease Mechanisms, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming Yunnan 650223, China
² Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming Yunnan 650204, China

ABSTRACT

Basal cell carcinoma (BCC) is the most common skin cancer worldwide, with incidence rates continuing to increase. Ultraviolet radiation is the major environmental risk factor and dysregulation of the Hedgehog (Hh) signaling pathway has been identified in most BCCs. The treatment of locally advanced and metastatic BBCs is still a challenge and requires a better animal model than the widely used rodents for drug development and testing. Chinese tree shrews (*Tupaia belangeri chinensis*) are closely related to primates, bearing many physiological and biochemical advantages over rodents for characterizing human diseases. Here, we successfully established a Chinese tree shrew BCC model by infecting tail skins with lentiviral SmoA1, an active form of Smoothened (Smo) used to constitutively activate the Hh signaling pathway. The pathological characteristics were verified by immunohistochemical analysis. Interestingly, BCC progress was greatly enhanced by the combined usage of lentiviral SmoA1 and shRNA targeting Chinese tree shrew *p53*. This work provides a useful animal model for further BCC studies and future drug discoveries.

Keywords: Chinese tree shrew; Basal cell carcinoma; Hedgehog

INTRODUCTION

Basal cell carcinoma (BCC) is the most common non-melanoma skin cancer (NMSC), accounting for over 80% of NMSC cases (Rubin et al., 2005). Exposure to ultraviolet radiation is the greatest oncogenic factor for this disease. Most BCCs occur in superficial sites, including the head, neck, trunk, and extremities (Bastiaens et al., 1998; Scrivener et al., 2002), whereas some sites, such as the axillae, breasts, perianal area, genitalia, palms, and soles, are readily ignored by dermatologists during medical examinations (de Giorgi et al., 2005; Rubin et al., 2005). Generally, human skin under both sun and non-sun exposure has the capability to form cancer, indicating that BCC formation could be a multifactor-induced oncogenic process with other genetic factors involved (De Giorgi et al., 2006). The most common histological BCC subtypes are nodular BCCs, followed by superficial BCCs and infiltrative BCCs (Bastiaens et al., 1998; Betti et al., 2012; Scrivener et al., 2002).

The incidence of BCC continues to increase worldwide (Lomas et al., 2012). Due to different standards, however, it is difficult to compare incidences among countries. Currently, Europe, North America, and Australia top the global incidence rates. For example, the rates have increased approximately 5% every year over recent decades in Europe (Lomas et al., 2012), and cases in the USA now exceed 2.8 million patients, outnumbering the total rates of all other cancers (Asgari et al., 2015; Rogers et al., 2015; Siegel et al., 2016) and accounting for 3,000 deaths annually (Madan, 2010; Mohan & Chang, 2014). Although the incidence of BCC obviously increases with age, the incidence in adults younger than 40 has also increased year by year (Christenson et al., 2005; Demers et al., 2005). Currently, it costs the government more than $40 million (USD) to provide medical care annually in USA (Chen et al., 2001; Mudigonda et al., 2010). In Australia, one in two people by the
The Hedgehog (Hh) signaling pathway is an evolutionarily conserved pathway known to play essential roles in embryonic development and adult tissue hemostasis and repair (Chen & Jiang, 2013). In general, the Hh ligand is bound to the secreted twelve-transmembrane receptor Patched-1 (Ptc1). Smoothened (Smo), a seven transmembrane receptor, is then activated by phosphorylation and other post-translational modifications, leading to accumulation in the primary cilium and induction of the Gli transcription factor to activate downstream gene expression (Yang et al., 2012). Malfunction of the Hh signaling pathway results in various developmental defects, including holoprosencephaly, cyclopia, limb abnormalities, and progression of tumors such as BCC and medulloblastoma (Teglund & Toftgård, 2010). Studies have demonstrated some Hh signaling component mutations associated with BCC development (De Zwaan & Haas, 2010; Lacour, 2002; Reifenberger et al., 2005). However, the predominant oncogenic mutations are those of the Ptc1 and Smo genes, which can cause abnormal constitutive activation of the Hh signaling pathway (Bonilla et al., 2016; Sekulic & Von Hoff, 2016; Xie et al., 1998). Although activation of the Gli transcriptional factor sequenced by Sufu protein loss of function should promote BCC progression, inactivated Sufu in mouse skin shows few or no BCCs (Li et al., 2014), suggesting that Ptc1 or Smo might be a better target for establishing a BCC animal model.

There are many therapies for the treatment of BCC in cancer patients, including the modulation of Hh signaling activities for invasive BCC (Sekulic et al., 2012; Tang et al., 2012; Von Hoff et al., 2009). Vismodegib (GDC-0449), a Smo specific antagonist approved by the Food and Drug Administration (FDA) in 2012, is used to treat metastatic or locally advanced BCCs (Diugosz et al., 2012). A recent study showed that an amino acid substitution at a conserved specific aspartic acid residue of a Smo mutation could confer BCC patients resistance to GDC-0449 treatment, suggesting that targeting Smo might be important for BCC treatment. As such, exploration of second-generation SMO inhibitors that are capable of overcoming acquired resistance is increasing (Yauch et al., 2009). Sonidegib (LDE225), another Smo antagonist approved by the FDA in 2015, is a clinical drug used for locally advanced BCC (Burness, 2015). It has also been reported that the antifungal drug itraconazole can suppress all known Smo drug-resistant mutants, thus inhibiting the Hh signaling pathway (Kim et al., 2013).

To further explore BCC pathogenesis, as well as develop new strategies for treating BCC, better animal models are required. Such models should conform to the conditions of patients and allow for: (1) the time of BCC induction to be defined and controllable; (2) the development of various stages and subgroups of human BCC; and (3) the inductivity of BCC in 100% of animals (Chen et al., 2009). To meet these requirements, many BCC models have been established. Most are transgenic mouse models, such as Ptc1 knockout mice (Arad et al., 2008; Asztterbaum et al., 1999; Nitzki et al., 2010; Skvara et al., 2011; So et al., 2004), or include constitutive activation of other Hh signaling pathway key regulators, such as oncogenic Smo, Gli1, or Gli2 mutation expressions driven by skin-specific keratin (K) 5, 6, or 14 promoters (Nitzki et al., 2012). In seven-week-old Sprague-Dawley rats, e.g., spontaneous BCC tumors were observed as single, reddish-brown subcutaneous masses located at the left inguinal region, basaoid cells showed lobular and cribriform growth with high mitotic rates, and cytokeratin 14 and cytokeratin 18 were expressed in nest tumor cells, thereby indicating that spontaneous BCC can occur in young rats (Lee et al., 2010). Nano-electro-ablation methods have been found to induce apoptosis efficiently in a Ptc1(+/−) K14-Cre-ER p53flo/fl mouse BCC model (Nuccitelli et al., 2012). Protein kinase A (PKA) activation by cAMP agonist forskolin inhibited BCC growth, particularly drug resistant BCC for Smo inhibitors, which was performed and evaluated in tamoxifen-induced 30-day-old postnatal mice which were born from male K14-CreERT2 crossed with female homozygous R26-SmoM2 (Makino & Mameros, 2012). Furthermore, introduction of Smoothened constitutive active form SmoA1 in mouse cerebellar granule neuron precursors was shown to cause a 48% incidence rate of medulloblastoma (Hallahan et al., 2004).

Inactivation of tumor suppressor p53 promotes tumorigenesis and is correlated with poor survival (Ghaderi & Haghighi, 2005; Lacour, 2002; Moles et al., 1993; Urano et al., 1995; Wang et al., 2017; Ziegler et al., 1993). Thus, the clues to the mutation of p53 in human BCCs show that their ablation might also contribute to tumor formation (Wörmann et al., 2016; Wu et al., 2014). Therefore, to imitate spontaneous BCCs in humans and speed up progression in animals, disruption of p53 could be an alternative.

Considering the distant relationship between humans and rodents, and the long period for non-human primate model establishment, we choose the Chinese tree shrew (Tupaia belangeri chinensis) as an animal model for BCC. The Chinese tree shrew, which belongs to Tupaiidae (Scandentia), is widely spread over Southeast Asia and Southwest China, including Yunnan province (Zhao et al., 2014). This tree shrew species possesses a variety of unique and notable physiological characteristics, including small adult body size, high brain-to-body mass ratio, short reproductive cycle and life span, low maintenance, and most importantly, a close affinity to primates (Fan et al., 2013). The recent elucidation of the genome of Tupaia belangeri chinensis confirmed the close genomic relationship between Tupaia belangeri and primates (Fan et al., 2013). As a favorable animal model, the tree shrew has been used for many human disease studies, including research on depression (Fuchs, 2005; Wang et al., 2011; 2012; 2013), drug addiction (Sun et al., 2012; Zhang et al., 2011), virus infection (Amako et al., 2010; Yan et al., 1996; Yang et al., 2005), bacterial infection (Li et al., 2012), breast cancer (Elliott et al., 1996; Ge et al., 2016; He et al., 2016; Xia et al., 2012), glioblastoma (Tong et al., 2017), thrombosis (Endo et al., 1997), metabolic diseases (Wu et al., 2013; 2016; Zhang et al., 2015; 2016), stem spermatogonium transgenics (Li et al., 2017), and myopia (Norton et al., 2006). Recently, pharmacological research through drug target prediction and genomic and
transcriptomic scale analysis has shown that more than half of the drug target proteins identified from the tree shrew genome demonstrate higher similarity to human targets than that of the mouse, as validated by the constitutive expression of proteinase-activated receptors (Zhao et al., 2014). The above studies indicate that over several years of research, the tree shrew has shown huge potential as an animal model for research of human diseases, including mental, nervous, infective, metabolic, and cancer diseases (Xiao et al., 2017; Xu et al., 2013; Yao, 2017), as well as drug safety (Zhao et al., 2014).

To establish a BCC model in the tree shrew, we constructed lentiviral vectors containing Hh signaling pathway constitutive activator SmoA1 tagged by GFP, which was used to trace the lentiviral infected tree shrew skin cells. We then infected the dorsal skins of 6-week-old tree shrews in vivo with both control and SmoA1 containing lentiviruses using one dose (10 μL) of the virus containing 5.6×10⁵ transducing units (TU). Two weeks later, hematoxylin-eosin (HE) staining was performed to examine the pathological phenotypes of the skins. The results showed the human BCC-like phenotype and remarkable pathological changes compared with reciprocal biopsies from the control virus. Interestingly, when we injected the virus into the tree shrew tail skins, the BCC tumor formed more easily than that on other parts of skin after only one dose containing 5μL of pCDH-SmoA1 virus (5.6×10⁵ TU) and 5μL of lentiviral shRNA targeting p53 (2×10⁵ TU). In summary, we successfully and efficiently established a BCC model using the tree shrew, which closely recapitulated the clinical phenomena. This animal model will help to better understand the fundamental mechanisms of BCC, and could be used for evaluating novel therapeutic strategies against BCC and pre-clinical drugs in the future.

MATERIALS AND METHODS

Animal use and care
Wild-type adult male tree shrews were provided by the Kunming Primate Research Center, Kunming Institute of Zoology (KIZ), Chinese Academy of Sciences (CAS). All experimental procedures and animal care and handling were performed under the standard guidelines approved by the Institutional Animal Care and Use Committee of the KIZ, CAS (SMKX2013023).

Plasmids construction and cell culture
A mSmoA1-6×myc fragment was collected from pGE-mSmoA1 digested by double restriction endonuclease with Hind III and Sac II, and was then cloned into pCDH empty expression vector digested by EcoR I and BamH I in blunting form. The short heparin RNA (shRNA) targeting sequences for tree shrew p53 (tsp53) were 1⁰: 5'-CCCTGACATCTTATCCTGGGT-3' and 2⁰: 5'-TTTGTGCCGCTTGCTGGAAG-3', and the control scramble shRNA sequence was 5'-GCACCATCGAGCTAATCGA-3'. The shRNA oligos were synthesized by BGI-Shenzhen (Shenzhen, China). The synthesized complementary oligo DNA was annealed by 95 °C boiling water and ligated with pKo1 plasmid. The product was transformed into DH5α competent cells and plated on LB agar. Individual colonies were randomly collected and shaken at 37 °C, with the plasmids then extracted using a plasmid extraction kit (Tiangen, Beijing, China) and checked by enzyme digestion and sequencing. Primary culture of tree shrew skin derived progenitor/stem cells (SKPs) was performed according to a previously validated method (Bejanska et al., 2007). Briefly, animals were euthanized by ethyl ether anesthesia and dissected for the generation of dorsal back skin and tail skin. All blood vessels, adipose, fascia, and muscle underlying the dermis were removed gently to reduce contamination by other cell types in the culture. The dissected skin tissues were minced into 1–2 mm² size pieces, transferred to a 15 mL conical tube for digestion, and submersed in 0.1% trypsin for 15–60 min at 37 °C. Afterwards, 10 mL of Dulbecco modified Eagle's medium (DMEM/F12) (Hyclone) supplemented with 10% fetal bovine serum (FBS) (Hyclone) was added to stop the trypsin digestion process. The samples were then centrifuged at 1 200 r/min and 4 °C for 6-8 min and resuspended in 1 mL of DMEM/F12 medium, and filtered through a 40 μm cell strainer. The flow-through samples were cultured continuously as SKP cells.

The HEK-293T cells were obtained from American type culture collection (ATCC, CAT#: CRL-3216) and cultured in DMEM high glucose (Hyclone), 10% FBS (Hyclone), 1% penicillin (Beyotime Biotechnology, China) and 1% streptomycin (Beyotime Biotechnology, China) in a 37 °C and 5% CO₂ incubator.

Lentiviral package and preparation
The lentiviruses were generated according to the manufacturer's protocols (Addgene, USA), with the viruses harvested at 48 h and 72 h after transfection and filtered with a 0.45 μm filter. The tree shrew SKPs were then infected with the viruses or the virus particles were concentrated by ultracentrifugation at 8 000 r/min and 4 °C for 3 h before in vivo infection. Polybrene (Sigma, USA) (final concentration 4 μg/mL) was added when the tree shrew SKPs were infected to promote infection efficiency as well as in vivo infection. Infected SKPs were screened with puromycin (Invitrogen, USA) after 72 h of infection, followed by cell amplification and identification.

Real-time quantitative PCR (qPCR)

The efficiency of tsp53 (ts: tree shrew) shRNA was tested in tree shrew SKPs. Total RNA was isolated using Trizol reagent (Takara, Japan) and reverse transcription was performed using an iScript cDNA Synthesis Kit according to the manufacturer’s instructions (Bio-Rad, USA). This was followed by quantitative real-time PCR using a SYBR Green Mix with Rox (Roche, USA). The primer sequences used were: tsGAPDH: 5′--ACGACCCCT TCAAGTCTG-3’and 5′-TCTCCATGTTGGAAGACA-3’; tsp53: 5′-CCACGGAAAGACTGGTTCAAT-3’ and 5′-ACGTGCAAGTGA CAGACTTG-3’.

Lentiviral injection

After ketamine anesthetic (40 μg/g), the hair on the dorsum and tail of the tree shrews was shaved, with depilatory paste then applied to remove fine hair. Next, the pCDH-mSmoA1 lentivirus (5.6×10⁵ TU), shRNA targeting tree shrew p53 gene lentivirus (shp53, 2×10⁵ TU), and control vector (pCDH-mSmoA1 group, www.zoores.ac.cn
intracutaneously injected with 5.6×10^5 TU virus/injection site. All trees were fixed for immunohistochemical analysis or immediately frozen by liquid nitrogen and stored at –80 °C.

HE staining

Normal skin tissues and tumors were preserved in 10% phosphate-buffered formalin. Tissues were then processed for paraffin embedding and cut into 4 μm thick sections. Section samples were subjected to standard hematoxylin and eosin (HE) staining.

Statistical analysis

All data were presented as means±SE of a minimum of three replicates. For all analyses, we evaluated statistical differences using the Student's t-test. Each experiment was performed at least three times. Differences were considered significant if the P value was <0.05 (**: P<0.05, ***: P<0.01, ****: P<0.001), compared with the control group.

RESULTS

We performed protein sequence alignment for the Smo protein among humans, tree shrews, and mice using Blast software (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The results showed that the core transmembrane domains as well as the C-terminal of the human, mouse, and tree shrew Smo proteins were highly conserved, although the tree shrew Smo also contained an elongated N-terminal overhang, whose structural and functional roles need to be further validated. While we found that the oncogenic SmoA1 mutation site (W539 in mice and W535 in humans) was highly conserved among all three species, as shown in Figure 1 (Taipale et al., 2000; Xie et al., 1998), we decided to induce BCC in tree shrew skins with the constitutive active form of SmoA1 for the following experiments (Chen et al., 2011). To validate the lentiviral titer and efficiency for tree shrew skin, we infected the following experiments (Chen et al., 2011). To validate the lentiviral titer and efficiency for tree shrew skin, we infected the following experiments (Chen et al., 2011). To validate the lentiviral titer and efficiency for tree shrew skin, we infected the following experiments (Chen et al., 2011). To validate the lentiviral titer and efficiency for tree shrew skin, we infected

mixture volume was approximately 10μL. Two weeks later, the pathologies of the lentivirus infected dorsal skins were analyzed by HE staining. We found that the pCDH-SmoA1 group exhibited human BCC-like pathological characteristics, such as hyperplasia of skin cells with hair follicle (HF) disruption, and pigmentation and nuclear explosion expansion (Figure 3C). However, black plaque did not develop into human-like BCC, even after a longer period. Since p53 ablation has been frequently observed in BCC and other tumors, which could possibly speed up the process of BCC (Rady et al., 1992; Soussi & Béroud, 2001; Soussi et al., 2000; Wijnhoven et al., 2005), we constructed lentiviral expressing shRNAs targeting tree shrew p53 with tdTomato expression driven by an individual PGK promoter, which was used to follow the shRNA expressing cells and tissues (Figure 4A). Fluorescence microscopy showed that positive red fluorescence approached 100% in tree shrew SKPs after lentiviral shp53-tdTomato infection (Figure 4B), and tree shrew Tp53 mRNA knockdown efficiency by lentiviral shRNAs was confirmed by real-time PCR compared with scramble shRNA control (Figure 4C).

It has been demonstrated previously that the vast majority of BCCs in a conditional mouse model (K5-TA:TRE–Gli2 bitransgenic mice) formed on the mouse tails, ears, extremities, and dorsal skin (Hutchin et al., 2005). We tested BCC formation efficiency in the tail skins of tree shrews using the above lentiviruses. The results (Figure 4D) indicated that both SmoA1-GFP and shp53-tdTomato successfully infected the tree shrew tail skin. Furthermore, obvious BCC plaque and mass formation were found in the pCDH-SmoA1 group two months later, and the pCDH-mSmoA1 and shp53 groups showed the most malignancies. Statistically, ~40% of tree shrews showed BCC-like phenotypes after four weeks following the SmoA1 viral-injection alone, and reached 60% after 6–8 weeks. Interestingly, more than 70% of tree shrews showed BCC-like phenotypes two weeks after SmoA1 and p53-shRNA viral-injection, which reached to 100% after four weeks (Figure 4F). These data suggest that the Hh signaling pathway constitutively activated by SmoA1 overexpression induced tree shrew BCC pathogenesis, and knockdown of tumor suppressor p53 could accelerate tree shrew BCC tumor progression.

DISCUSSION

Vismodegib has been used recently for metastatic or advanced BCC in clinical trials, showing good effect in phase I trials (Graham et al., 2011; Lorusso et al., 2011; Von Hoff et al., 2009), but only 30% of metastatic and 43% of locally advanced BCC patients treated with vismodegib have demonstrated a good response in Phase II trials (Sekulic et al., 2012). In Phase I study of sonidegib, 37% of BCC patients achieved partial or complete response, whereas 42% of BCC patients in Phase 2 responded well to treatment with 200 mg of sonidegib per day orally (Migden et al., 2015). Collectively, these studies suggest that downstream inhibitors of Hh signaling and a combination of therapies targeting other pathways using better animal models are required. Here, we showed that lentiviral injection of SmoA1 and shp53 could induce BCCs in tree shrew skins successfully.
Protein sequence alignment results showed that Smoothened (Smo) was highly conserved among tree shrews (TSDB Protein sequence: TSDBP00001058), mice (GenBank Accession No: NM_176996.4), and humans (GenBank Accession No: NM_005631.4). The Smoothened A1 site was identical among the three species and is marked by a black frame. Ts: tree shrew.

In addition, a recent study indicated that the MK-4101 molecule can attenuate the Hh signaling pathway through inhibition of Gli, alteration of IGF, and Wnt signaling pathway activities, thus proving to be a promising therapeutic drug for BCC patients (Filocamo et al., 2016). A second-generation antifungal drug posaconazole, which showed distinct mechanisms from cyclopamine or cyclopamine competitive inhibitors, exhibits better drug-drug interaction and fewer side effects than current SMO inhibitors, and could provide a novel strategy for clinical drug combinational therapy (Chen et al., 2016).

In general, older adults suffering from BCC receive Hh signaling pathway inhibitor treatment. Premenopausal women are also subjected to menopause due to the reversal of chorionic hormone receptor inhibition (Simone et al., 2016). Furthermore, many dermatologists are not familiar with the side effects of such treatment, thus consulting professional practitioners about teratogenicity and sequelae of ovarian failure is required. New or persistent ulcers, nodules, or erythema after three months of treatment with Hh signaling pathway inhibitors have been found by biopsy (Simone et al., 2016; Zhu et al., 2014), therefore all skin should be monitored during the whole treatment process (Simone et al., 2016; Zhu et al., 2014). At the same time, non-BCC damage should also be given comprehensive treatment because synchronous occult amelanotic melanoma has been reported in 25% (3/12) of BCC patients (Simone et al., 2016; Zhu et al., 2014). Two BCC patients, five years after Hh signaling pathway inhibitor treatment, have survived by paying close attention to and interfering with various side effects (Jacobsen et al., 2017).
Figure 2  Lentivirus SmoA1 efficiently infected tree shrew SKPs
A: Representative image of tree shrew SKPs; B: SmoA1 lentivirus infected SKPs with high efficiency. pCDH empty vector was used as the control; C: Relative virus titer determination in SKPs by fluorescence microscopy between pCDH vector and pCDH-SmoA1 lentivirus groups; D: Relative mRNA expressions of Gli1 and Ptc1 were determined by real-time PCR, cells were SKPs infected with indicated lentiviruses. Data are presented as mean±SE (*: P<0.5; **: P<0.1).

Figure 3  Over-expression of SmoA1 induced BCC-like hyperplasia in dorsal skins of the tree shrews in vivo
A: Flow chart for lentivirus preparation; B: Viral injection design in dorsal areas of tree shrew skin; C: Representative images under different magnifications (4×, 10×, 20×, 40×) with HE staining. Results showed BCC-like hyperplasia of skin cells with hair follicle (HF) disruption (arrow head), pigmentation (asterisk), and nuclear explosion expansion after viral injection two weeks later. The pCDH-vector served as the control viral injection.
Figure 4  BCC formation in tree shrew tail skins by combined usage of SmoA1 and shp53 viruses

A: Diagram of two shRNAs targeting tree shrew p53; B: Lentivirus expressing shRNAs co-expressing tdTomato infected SKPs in vitro efficiently; C: shp53 knockdown efficiency was verified by real-time PCR, cells were SKPs infected with indicated viruses; D: The tree shrew tail skins formed BCC tumors efficiently. Trypan blue, tdTomato, and GFP indicate the locations of the injected viruses; E: Representative images of BCC originated from the tails of tree shrews with indicated treatment (empty vector, SmoA1 or/in combination with shp53, respectively); F: Percentage curve of tumor-free tree shrews shows that the combination of lentiviral SmoA1 and shp53 (median time: two weeks) accelerated BCC formation in tails compared with SmoA1 alone (median time: six weeks). n=6, separately.

Recent research, which established EGFP-tagged transgenic tree shrews following spermatogonial stem cell (SSC) transplantation, provided a good approach for the generation of multiple human disease models using the tree shrew by gene editing manipulation (Li et al., 2017). Although BCC was not observed in DMBA/TPA combination treated wild-type mice (Indra et al., 2007), it has been successfully generated in Ptchflox/floxCD4Cre−/− mice (Uhmann et al., 2014). Thus, it would be interesting to combine DMBA/TPA with lentiviral SmoA1 and p53-shRNA in tree shrew skins in the future.

PTEN (phosphatase and tensin homolog deleted on chromosome 10) plays critical roles in tissue homeostasis and cancer development, and is a commonly mutated tumor suppressor gene (Salmena et al., 2008). Earlier research showed that 100% of mice with complete Pten deficiency in their keratinocytes and a proportion with Pten heterozygosity, developed NMSC spontaneously (Suzuki et al., 2003). Deletions of Pten in BCC are an infrequent event (Quinn et al., 1994), implicating that Pten is a significant suppressor of non-melanoma skin tumorigenesis (Hertzler-Schaefer et al., 2014; Macdonald et al., 2014; Ming & He, 2009). To improve the BCC tree shrew model, loss of PTEN function as well as UV radiation might stimulate low-level Hh signaling caused by mutations in Hh pathway components via the up-regulation of the PI3K/AKT pathway and DNA damage-related signaling activation, respectively (Ming & He, 2009; Ouhtit et al., 1998).

BCCs are closely related to abnormal oncogenic activation of the Hh pathway, which can have different functions and mechanisms between different species, the closer relationship between different species, the closer functions and mechanisms of relative genes. These similar biological characteristics between animals and human allow for the mimicry of human tumor progression. However, there are limits to murine animal models. Genome analysis has verified that the tree shrew is closely related to primates (Fan et al., 2013) and is superior to murine species. Small body size, low-cost maintenance, short reproductive cycle and life span, and its close relationship to primates make the tree shrew a safer, more efficient, and more predictable animal model, therefore surpassing murine species in the testing of drug efficacy and safety and deciphering the
pathogenesis of BCC. Here we established, for the first time, a tree shrew BCC model that successfully simulated human BCC pathological features. However, the molecular markers of BCCs are needed to confirm this model at the molecular level. It would be interesting to use current clinical BCC-treatment drugs, such as vismodegib, to validate the efficiency and effects of the tree shrew BCC model. Furthermore, this model could be used to screen novel natural compounds that might function alone or in synergy with current clinical drugs to treat BCC.

REFERENCES

Abarca JF, Casiccia CC. 2002. Skin cancer and ultraviolet-B radiation under the Antarctic ozone hole: southern hemisphere. *Photodermatology, Photoimmunology & Photomedicine*, 18(6): 294-302.

Amako Y, Tsukiyama-Kohara K, Katsume A, Hirata Y, Sekiguchi S, Tobita Y, Hayashi Y, Hishima T, Funata N, Yonekawa H, Kohara M. 2010. Pathogenesis of hepatitis C virus infection in *Tupaia belangeri*. *Journal of Virology*, 84(1): 303-311.

Arad S, Zattra E, Hebert J, Epstein EH, Jr., Goukassian DA, Gilchrest BA. 2008. Topical thymidine dinucleotide treatment reduces development of ultraviolet-induced basal cell carcinoma in *Ptch-1-/-* mice. *The American Journal of Pathology*, 172(5): 1248-1255.

Asgari MM, Moffet HH, Ray GT, Quesenberry CP. 2015. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998-2012. *JAMA Dermatology*, 151(9): 976-981.

Aszterbaum M, Beech J, Epstein EH, Jr. 1999. Ultraviolet radiation mutagenesis of hedgehog pathway genes in basal cell carcinomas. *Journal of Investigative Dermatology Symposium Proceedings*, 4(1): 41-45.

Bastiaens MT, Hoefnagel JJ, Vermeer BJ, Bavinck JNB, Brujin JA, Westendorp RGJ. 1998. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinomas indicate different types of tumors. *Journal of Investigative Dermatology*, 110(6): 880-884.

Betti R, Radaelli G, Crosti C, Ghiozzi S, Moneghini L, Menni S. 2012. Margin involvement and clinical pattern of basal cell carcinoma with mixed histology. *Dermatology*, 217(5): 1248-1255.

Betti R, Radaelli G, Crosti C, Ghiozzi S, Moneghini L, Menni S. 2012. Margin involvement and clinical pattern of basal cell carcinoma with mixed histology. *Dermatology*, 217(5): 1248-1255.

Burgess CB. 2015. Sonidegib: first global approval. *Drugs*, 75(13): 1559-1566.

Chen BY, Sasai N, Ma GQ, Yue T, Jia JH, Briscoe J, Jiang J. 2011. Sonic Hedgehog dependent phosphorylation by CK1α and GRK2 is required for ciliary accumulation and activation of smoothened. *PLoS Biology*, 9(6): e1001083.

Chen YB, Jiang J. 2013. Decoding the phosphorylation code in Hedgehog signal transduction. *Cell Research*, 23(2): 186-200.

Chen YH, Wang YH, Yu TH, Wu HJ, Pai CW. 2009. Transgenic zebrafish line with over-expression of Hedgehog on the skin: a useful tool to screen Hedgehog-inhibiting compounds. *Transgenic Research*, 18(6): 855-864.

Chrestenson LJ, Borrowman TA, Vachon CM, Tolleson MM, Otey CC, Weaver AL, Roenigk RK. 2005. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. *JAMA*, 294(6): 681-690.

di Giorgi V, Salvini C, Massi D, Raspolini MR, Carli P. 2005. Vulvar basal cell carcinoma: retrospective study and review of literature. *Gynecologic Oncology*, 97(1): 192-194.

Di Giorgi V, Massi D, Lotti T. 2006. Basal-cell carcinoma. *The New England Journal of Medicine*, 354(7): 769-771.

De Zwaan SE, Haass NK. 2010. Genetics of basal cell carcinoma. *Australasian Journal of Dermatology*, 51(2): 81-92.

Demers AA, Nugent Z, Mihalciou C, Wiseman MC, Kliewer EV. 2005. Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. *Journal of the American Academy of Dermatology*, 53(2): 320-328.

Dlugosz A, Agrawal S, Kirkpatrick P. 2012. Vismodegib. *Nature Reviews Drug Discovery*, 11(6): 437-438.

Elliot OS, Elliot MW, Lisco H. 1966. Breast cancer in a tree shrew (*Tupaia glis*). *Nature*, 211(5053): 1105.

Endo H, Mifune H, Maeda S, Kimura J, Yamada J, Rerknamnuaychoke W, Chungsamarmyart N, Ogawa K, Kurohmaru M, Hayashi Y. 1997. Cardiac-like musculature of the intrapulmonary venous wall of the long-clawed shrew (*Sorex unguiculatus*), common tree shrew (*Tupaia glis*) and common marmoset (*Callithrix jacchus*). *Anatomical Record-Advances in Integrative Anatomy & Evolutionary Biology*, 247(1): 46-52.

Fan Y, Huang ZY, Cao CC, Chen CS, Chen YX, Fan DD, He J, Hou HL, Lu H, Xu HT, Jiang XT, Lai R, Lang YS, Liang B, Liao SG, Mu D, Ma YY, Niu YY, Sun XQ, Xiao JQ, Xiao J, Xiong QZ, Xu L, Yang L, Zhang Y, Zhao W, Zhao XD, Zheng YT, Zhou JM, Zhu YB, Zhang GJ, Wang J, Yao YG. 2013. Genome of the Chinese tree shrew. *Nature Communications*, 4: 1426.

Filocamo G, Brunetti M, Colaceci F, Sasso R, Tanori M, Pasquali E, Alfonsi R, Mancuso M, Saran A, Lahm A, Di Marcotullio L, Steinkühler C, Pazzaglia S. 2016. MK-4101, a Potent inhibitor of the hedgehog pathway, is highly active against medulloblastoma and basal cell carcinoma. *Molecular Cancer Therapeutics*, 15(6): 1177-1189.

Fuchs E. 2005. Social stress in tree shrews as an animal model of depression: an example of a behavioral model of a CNS disorder. *CNS Spectrums*, 10(3): 182-190.

Ge GZ, Xia HJ, He BL, Zhang HL, Liu WJ, Shao M, Wang CY, Xiao J, Ge F, Li FB, Chen CS. 2016. Generation and characterization of a breast carcinoma model by PyMT overexpression in mammary epithelial cells of tree shrew, an animal close to primates in evolution. *International Journal of Cancer*, 138(3): 642-651.

Ghadiri R, Haghighi F. 2005. Immunohistochemistry assessment of p53 protein in Basal cell carcinoma. *Iranian Journal of Allergy, Asthma and
Li ZJ, Salvini C, Massi D, Raspolini MR, Carli P. 2005. Vulvar basal cell carcinoma: retrospective study and review of literature. Gynecologic Oncology, 97(1): 192-194.

Graham RA, Lum BL, Cheeth S, Jin JY, Jorga K, Von Hoff DD, Rudin CM, Reddy JC, Low JA, Lorusso PM. 2011. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. *Clinical Cancer Research: an official journal of the American Association for Cancer Research*, 17(8): 2512-2520.

Hallahan AR, Pritchard JI, Hansen S, Benson M, Stoeck J, Hatton BA, Russell TL, Ellenbogen RQ, Bernstein ID, Beachy PA, Olson JM. 2004. The Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. *Genes & Development*, 19(2): 214-223.

Indra AK, Castaneda E, Antal MC, Jiang M, Messadeq N, Meng XJ, Loehr CV, Gariglio P, Kato S, Wahli W, Desvergne B, Metzger D, Chambon P. 2007. Malignant transformation of DMBA/TPA-induced papillomas and nevi in the skin of mice selectively lacking retinoid-X-receptor α in epidermal keratinocytes. *Journal of Investigative Dermatology*, 127(5): 1250-1260.

Jacobsen AA, Kyrd AR, Strasswimmer J. 2017. Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma. *Journal of the American Academy of Dermatology*, 76(4): 767-768.

Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, Guo H, Wu Y, Ji S, Ma YH, Ji S, Yang L, Huang Y, Wang J, Zhang YH, Nie WH, Lui CH, Yan LZ, Ban WZ, Guo J, Li X, Zhai Y, Zhou T, Zhang Y. 2012. Two bacterial infection models in tree shrew for evaluating the efficacy of antimicrobial agents. *Zoological Research*, 33(1): 1-6.

Li JZ, Mack SC, Mack TH, Angers S, Taylor MD, Hui CC. 2014. Evasion of p53 and G0/M checkpoints are characteristic of Hh-driven basal cell carcinoma. *Oncogene*, 33(20): 2674-2680.

Lomas A, Leonard-Bee J, Bath-Hextall F. 2012. A systematic review of worldwide incidence of nonmelanoma skin cancer. *British Journal of Dermatology*, 166(5): 1069-1080.

LoRusso PM, Rudin CM, Reddy JC, Tribes R, Weiss GJ, Borad MJ, Hanno CL, Brahmer JR, Chang I, Darbonne WC, Graham RA, Zerovitz KL, Low JA, Von Hoff DD. 2011. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. *Clinical Cancer Research*, 17(8): 2502-2511.

Macdonald FH, Yao D, Quinn JA, Greenhalgh DA. 2014. PTEN ablation in Rasαv/fos skin carcinogenesis invokes p53-dependent p21 to delay conversion while p53-independent p21 limits progression via cyclin D1/E2 inhibition. *Oncogene*, 33(32): 4132-4143.

Madan V, Lear JT, Szemies RM. 2010. Non-melanoma skin cancer. *The Lancet*, 375(9715): 673-685.

Makindan E, Mameros AG. 2012. Protein kinase A activation inhibits oncogenic Sonic hedgehog signalling and suppresses basal cell carcinoma of the skin. *Experimental Dermatology*, 21(11): 847-852.

Migden MR, Guminiski A, Guttormer R, Dirix L, Lewis KD, Comberpale P, Herd RM, Kuchadkar R, Trefzer U, Gogov S, Pallaud C, Yi TT, Mone M, Kastz L, Loqiao C, Stratigos AJ, Schulze H, Plummer R, Chang ALS, Cornellis S, Lear JT, Sellami D, Dummer R. 2015. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. *The Lancet Oncology*, 16(6): 716-728.

Ming M, He YY. 2009. PTEN: new insights into its regulation and function in skin cancer. *Journal of Investigative Dermatology*, 129(9): 2109-2112.

Mohan SV, Chang ALS. 2014. Advanced basal cell carcinoma: epidemiology and therapeutic innovations. *Current Dermatology Reports*, 3(1): 40-45.

Moles JP, Moyret C, Guillot B, Jeanteur P, Guilhou JJ, Thellet C, Basset-Séguin N. 1993. p53 gene mutations in human epithelial skin cancers. *Oncogene*, 8(3): 583-588.

Mudigonda T, Pearce DJ, Yentzer BA, Williford P, Feldman SR. 2010. The economic impact of non-melanoma skin cancer: a review. *Journal of the National Comprehensive Cancer Network*, 8(8): 888-896.

Nitzki F, Zibat A, König S, Wijgerde M, Rosenberger A, Brembeck FH, Carstens PO, Frommhold A, Uhmahn A, Klinger A, Reifenberger J, Pukrop T, Abergro F, Schulz-Schaefer W, Hahn H. 2010. Tumor stroma-derived Wnt5a induces differentiation of basal cell carcinoma of Pch-mutant mice via CaMKII. *Cancer Research*, 70(7): 2739-2748.

Norton TT, Amedo AO, Siegwart JT, Jr. 2006. Darkness causes myopia in visually experienced tree shrews. *Investigative Ophthalmology & Visual Science*, 47(11): 4700.

Nuccitelli R, Tran K, Athos B, Kreis M, Nuccitelli P, Chang KS, Epstein EH, Jr., Tang JY. 2012. Nanoelectroablation therapy for murine basal cell carcinoma. *Biochemical and Biophysical Research Communications*, 424(3): 446-450.

Outhit A, Nakazawa H, Armstrong BK, Kricker A, Tan E, English DR. 1998. UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal cell carcinoma. *Journal of the National Cancer Institute*, 90(7): 523-531.

Quinn AG, Sikkink S, Rees JL. 1994. Basal cell carcinomas and squamous cell carcinomas of human skin show distinct patterns of chromosome loss. *Cancer Research*, 54(17): 4756-4759.
Rady P, Scinicariello F, Wagner RF, Jr., Tyring SK. 1992. p53 mutations in basal cell carcinomas. Cancer Research, 52(13): 3804-3806.

Rawashdeh MA, Mataika I. 2004. Basal cell carcinoma of the maxillofacial region: site distribution and incidence rates in Arab/Jordanians, 1991 to 2000. Journal of Oral and Maxillofacial Surgery, 62(2): 145-149.

Reifenberger J, Wolter M, Knobbe CB, Köhler B, Schönicker A, Schwanächter C, Kumar K, Blaschke B, Ruzicka T, Reifenberger G. 2005. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. British Journal of Dermatology, 152(1): 43-51.

Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. 2015. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatology, 151(10): 1081-1086.

Rubin AI, Chen EH, Ratner D. 2005. Basal-cell carcinoma. The New England journal of medicine, 353(21): 2262-2269.

Salmena L, Carracedo A, Pandolfo PP. 2008. Tenets of PTEN tumor suppressor. Cell, 133(3): 403-414.

Scrivener Y, Grosshans E, Cribier B. 2002. Variations of basal cell carcinoma with vismodegib hedgehog inhibitor therapy. The Journal of Investigative Dermatology, 119(6): 1264-1269.

Simone PD, Schwarz JM, Strasswimmer JM. 2016. Four-year experience with vismodegib hedgehog inhibitor therapy. Journal of the American Academy of Dermatology, 74(6): 1264-1269.

Skvara H, Kalthoff F, Meingassner JG, Wolff-Winiski B, Aschauer H, Kelleher JF, Wu X, Pan SF, Mickel L, Schuster C, Story G, Jaliil A, David OJ, Emotie C, Antunes AMC, Rose K, Decker J, Carlson I, Gardner H, Stuetz A, Bertolino AP, Stingl G, De Rie MA. 2011. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. The Journal of Investigative Dermatology, 131(8): 1735-1744.

Siegel RL, Miller KD, Jemal A. 2016. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians, 66(1): 7-30.

Simone PD, Schwarz JM, Strasswimmer JM. 2016. Four-year experience with vismodegib hedgehog inhibitor therapy. Journal of the American Academy of Dermatology, 74(6): 1264-1269.

So PL, Lee K, Hebert J, Walker P, Lu Y, Hebert J, Walker P, Lu Y. 2013. Chronic stress modifies hair follicle morphogenesis and tumor formation in mice and is associated with patient survival. Gastroenterology, 151(1): 180-193.e12.
Wu DW, Lee MC, Wang J, Chen CY, Cheng YW, Lee H. 2014. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer. Oncogene, 33(12): 1515-1526.

Wu XY, Li YH, Chang Q, Zhang LQ, Liao SS, Liang B. 2013. Streptozotocin induction of type 2 diabetes in tree shrew. Zoological Research, 34(2): 108-115. (in Chinese)

Wu XY, Xu HB, Zhang ZG, Chang Q, Liao SS, Zhang LQ, Li YH, Wu DD, Liang B. 2016. Transcriptome profiles using next-generation sequencing reveal liver changes in the early stage of diabetes in tree shrew (Tupaia belangeri chinensis). Journal of Diabetes Research, 2016: 6238526.

Xia HJ, Wang CY, Zhang HL, He BL, Jiao JL, Chen CS. 2012. Characterization of spontaneous breast tumor in tree shrews (Tupaia belangeri chinensis). Zoological Research, 33(1): 55-59. (in Chinese)

Xiao J, Liu R, Chen CS. 2017. Tree shrews (Tupaia belangeri) as a novel laboratory disease animal model. Zoological Research, 38(3): 127-137.

Xie JW, Murone M, Luo SM, Ryan A, Gu QM, Zhang CH, Bonifas JM, Lam CW, Hynes M, Goddard A, Rosenthal A, Epstain EH, Jr., De Sauvage FJ. 1998. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature, 391(6662): 90-92.

Xu L, Zhang Y, Liang B, Li LB, Chen CS, Chen YB, Zhou JM, Yao YG. 2013. Tree shrews under the spotlight: emerging model of human diseases. Zoological Research, 34(2): 59-69. (in Chinese)

Yan RQ, Su JJ, Huang DR, Gan YC, Yang C, Huang GH. 1996. Human hepatitis B virus and hepatocellular carcinoma. II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1. Journal of Cancer Research and Clinical Oncology, 122(5): 289-295.

Yang CP, Chen WL, Chen YB, Jiang J. 2012. Smoothened transduces Hedgehog signal by forming a complex with Evc/Evc2. Cell Research, 22(11): 1593-1604.

Yang EB, Cao J, Su JJ, Chow P. 2005. The tree shrews: useful animal models for the viral hepatitis and hepatocellular carcinoma. Hepatogastroenterology, 52(62): 613-616.

Yao YG. 2017. Creating animal models, why not use the Chinese tree shrew (Tupaia belangeri chinensis)? Zoological Research, 38(3): 118-126.

Yauch RL, Dijkgraaf GJP, Aliche B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan ZY, Seshagiri S, Hahn CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ. 2009. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science, 326(5952): 572-574.

Zhang LQ, Chang Q, Wang JY, Liao SS, Wu XY, Chen CY, Liang B. 2015. Cholesterol induces lipoprotein lipase expression in a tree shrew (Tupaia belangeri chinensis) model of non-alcoholic fatty liver disease. Scientific Reports, 5(1): 15970.

Zhang LQ, Wu XY, Liao SS, Li YH, Zhang ZG, Chang Q, Xiao RY, Liang B. 2016. Tree shrew (Tupaia belangeri chinensis), a novel non-obese animal model of non-alcoholic fatty liver disease. Biology Open, 5(10): 1545-1552.

Zhang QY, Fan XN, Cao Y. 2011. Expression of cannabinoid and opioid receptors in nervous as well as immune systems of Macaca mulatta and Tupaia belangeri. Zoological Research, 32(1): 31-39. (in Chinese)

Zhao F, Guo XL, Wang YJ, Liu J, Lee WH, Zhang Y. 2014. Drug target mining and analysis of the Chinese tree shrew for pharmacological testing. PLoS One, 9(8): e104191.

Zhu GA, Sundram U, Chang AL. 2014. Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. JAMA Dermatology, 150(9): 970-973.

Ziegler A, Leffell DJ, Kunala S, Sharma HW, Galani M, Simon JA, Halperin AJ, Baden HP, Shapiro PE, Bale AE. 1993. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proceedings of the National Academy of Sciences of the United States of America, 90(9): 4216-4220.